Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma

NCT02155634 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02155634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02155634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Withdrawn
Start date
July 31, 2014
Completion date
March 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

blood protein disorders, hematologic diseases, multiple myeloma, neoplasms, paraproteinemias, plasma cells, therapeutic uses